SCM
MLNT

Stonepine Capital Management’s Melinta Therapeutics, Inc. Common Stock MLNT Stock Holding History

Stonepine Capital Management’s Portfolio MLNT Stock Details MLNT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-391,719
Closed -$7.74M – 32
2018
Q3 		$7.74M Buy
391,719
+381,279
+3,652% +$9.64M 4.52% 7
2018
Q2 		$331K Buy
+10,440
New +$376K 0.2% 24

Other funds holding MLNT

OH
Oikos Holdings New York $422M AUM 13.79% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Stonepine Capital Management's MLNT Position: Q4 2018 in Review

Stonepine Capital Management sold out of Melinta Therapeutics, Inc. Common Stock (MLNT) in Q4 2018, closing a stake of 391,719 shares — an estimated $7.74M sold.

Stonepine Capital Management first reported a position in MLNT in Q2 2018 and held it in 2 quarters. The position peaked at $7.74M in Q3 2018. 77 funds tracked by Wall St. Rank hold MLNT as of Q4 2018.

  • Stonepine Capital Management reported no remaining Melinta Therapeutics, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Stonepine Capital Management sold 391,719 Melinta Therapeutics, Inc. Common Stock shares in Q4 2018, an estimated $7.74M.
  • Stonepine Capital Management first reported a position in Melinta Therapeutics, Inc. Common Stock in Q2 2018 and held it in 2 quarters.
  • Stonepine Capital Management's Melinta Therapeutics, Inc. Common Stock position peaked at $7.74M in Q3 2018.
  • 77 funds tracked by Wall St. Rank held Melinta Therapeutics, Inc. Common Stock as of Q4 2018.

Based on Stonepine Capital Management's 13F filing for Q4 2018, filed 13 Feb 2019.